Finding the right CMC advisor can become difficult when development timelines are tight, technical information is distributed across manufacturers, laboratories and internal teams, and decisions made today can affect the quality dossier later in the product lifecycle. Companies may have strong scientific expertise in-house, but still lack the capacity to coordinate CMC inputs, prepare submission-ready... View Article
For biotech companies, Medical Affairs can become a pressure point long before a full internal function is in place. As clinical programmes advance, evidence expands and launch planning begins, teams may suddenly need scientific communication, stakeholder engagement, medical education and medical information capabilities at the same time. The right medical affairs consultant can help close... View Article
A company may have extensive regulatory documentation in place and still not have a clear answer to a critical question: where does the current regulatory position fall short of what is actually required? Differences can exist between approved information, supporting documentation, implemented changes, authority commitments and current regulatory expectations. In this context, experienced regulatory affairs... View Article
Rare disease companies bringing a new therapy to market face a distinct medical education challenge: awareness of the disease itself may still be limited. Healthcare professionals may encounter only a small number of affected patients, symptoms can overlap with more common conditions, and diagnosis may depend on recognising when specialist referral or further testing is... View Article
In oncology, the educational challenge is rarely a lack of information. The greater problem is timing: new biomarkers, indications, combination regimens and treatment sequences can alter clinical questions faster than a conventional education plan can be updated. For pharmaceutical and biotech teams, oncology medical education therefore has to remain aligned with a treatment landscape that... View Article
A veterinary PSMF may appear to be a documentation requirement, but preparing one that is complete, internally consistent and ready for regulatory scrutiny requires much more than filling predefined sections. Information must be collected from across the wider veterinary pharmacovigilance system, verified against current practice and presented in a way that clearly demonstrates how the... View Article
Advanced therapy medicinal products (ATMPs) combine complex science with manufacturing processes that can continue to evolve throughout clinical development. For developers, the challenge is not only producing a consistent product, but building a quality strategy that can support changing process knowledge, analytical capability and future regulatory expectations. This is where experienced regulatory affairs consulting can... View Article
For biotech companies developing innovative therapies, communication with regulatory authorities can influence key development decisions. Yet limited internal regulatory resources, complex scientific questions and evolving evidence can make these interactions difficult to prepare and manage. This is where experienced biotech regulatory consulting can provide valuable support. When regulatory questions are poorly framed, scientific positions are... View Article
Pharmaceutical Medical Affairs teams are expected to deliver scientifically rigorous, relevant and engaging education while managing increasingly complex evidence, multiple stakeholders and demanding timelines. Yet when specialist expertise or additional capacity is needed, expanding the delivery structure does not always solve the problem. What teams often need is an experienced medical education specialist who can... View Article
Medicine shortages are becoming an increasingly important challenge for pharmaceutical companies across the EU, with potential consequences for continuity of supply, regulatory compliance and, most importantly, patient care. Supply chain vulnerabilities, manufacturing and quality issues, unexpected changes in demand or limited alternatives can all contribute to disruptions that may ultimately affect medicine availability. For Marketing... View Article